Abacavir/lamivudine/zidovudine — Competitive Intelligence Brief

Abacavir/lamivudine/zidovudine (Abacavir/lamivudine/zidovudine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nucleoside reverse transcriptase inhibitor (NRTI) combination. Area: Infectious Disease / Virology.

marketed Nucleoside reverse transcriptase inhibitor (NRTI) combination HIV reverse transcriptase Infectious Disease / Virology Small molecule

Target snapshot

Abacavir/lamivudine/zidovudine (Abacavir/lamivudine/zidovudine) — Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections. This combination of three nucleoside reverse transcriptase inhibitors blocks HIV reverse transcriptase to prevent viral replication.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Abacavir/lamivudine/zidovudine TARGET	Abacavir/lamivudine/zidovudine	Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections	marketed	Nucleoside reverse transcriptase inhibitor (NRTI) combination	HIV reverse transcriptase
Atripla or Stribild	Atripla or Stribild	Fred Hutchinson Cancer Center	marketed	Antiretroviral combination therapy (NRTI/NNRTI or INSTI-based)	HIV reverse transcriptase, HIV integrase
DOR/DTG/3TC	DOR/DTG/3TC	Insel Gruppe AG, University Hospital Bern	marketed	Antiretroviral combination (NNRTI + INSTI + NRTI)	HIV reverse transcriptase, HIV integrase
JULUCA	JULUCA	ViiV Healthcare	marketed	Antiretroviral combination (integrase inhibitor + NNRTI)	HIV integrase and HIV reverse transcriptase
Standard Triple	Standard Triple	University of Alberta	marketed	Antiretroviral combination therapy	HIV reverse transcriptase, HIV protease (depending on formulation)
First-line Antiretroviral Therapy	First-line Antiretroviral Therapy	UPECLIN HC FM Botucatu Unesp	marketed	Antiretroviral combination therapy (NRTI/NNRTI/PI/INSTI)	HIV reverse transcriptase, HIV protease, HIV integrase (depending on regimen components)
Atazanavir, ritonavir, lamivudine	Atazanavir, ritonavir, lamivudine	Catholic University of the Sacred Heart	marketed	Antiretroviral combination (protease inhibitor + NRTI)	HIV protease, HIV reverse transcriptase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nucleoside reverse transcriptase inhibitor (NRTI) combination class)

1. Medical Research Council · 2 drugs in this class
2. Bristol-Myers Squibb · 1 drug in this class
3. Fundacion SEIMC-GESIDA · 1 drug in this class
4. GlaxoSmithKline · 1 drug in this class
5. Janssen Scientific Affairs, LLC · 1 drug in this class
6. Merck Sharp & Dohme LLC · 1 drug in this class
7. National Institute of Allergy and Infectious Diseases (NIAID) · 1 drug in this class
8. Tibotec, Inc · 1 drug in this class
9. University of North Carolina, Chapel Hill · 1 drug in this class
10. Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections · 1 drug in this class